m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00306)
Name
CMPD1
Synonyms
MAPKAPK2a inhibitor
    Click to Show/Hide
Status
Investigative
Structure
Formula
C22H20FNO2
InChI
1S/C22H20FNO2/c23-21-6-2-1-5-20(21)17-10-8-16(9-11-17)4-3-7-22(26)24-18-12-14-19(25)15-13-18/h1-2,5-6,8-15,25H,3-4,7H2,(H,24,26)
InChIKey
ODYAQBDIXCVKAE-UHFFFAOYSA-N
PubChem CID
11382492
TTD Drug ID
D0O7UT
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MAPK-activated protein kinase 2 (MAPKAPK2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for CMPD1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMPD1 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54. doi: 10.1021/jm0611004. Epub 2007 May 5.